Parexel to present commercialisation research at Annual European Congress

Parexel's commercialisation experts are to discuss methods of maximising product value with attendees at the upcoming 14th Annual European Congress.

The biopharmaceutical services giant will consider the issue from the item launch and over the entire lifecycle at the event, which will take place between November 5th and 8th in Madrid.

Parexel will be located at stands 53 and 54 at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) at the congress, which offers attendees the opportunity to increase their knowledge on reimbursement strategies.

Additionally, information will be given on how to align these methods with clinical development to gather specific data required to demonstrate product value.

Parexel experts will conduct numerous sessions at the ISPOR event, including a symposium entitled Integrated Regulatory and Commercial Planning: Internal Approaches and Value to Payers by vice-president Richard Morton.

The biopharmaceutical company reported its first quarter fiscal year 2012 financial results last month, with consolidated revenue increasing by 6.4 percent year on year to $314.7 million (196.8 pounds).